Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
基本信息
- 批准号:8497661
- 负责人:
- 金额:$ 4.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AfricaAntimalarialsAttentionBiochemistryCessation of lifeCharacteristicsChinaChloroquineChloroquine resistanceCountryDataDevelopmentDihydrofolate ReductaseDihydropteroate SynthaseDrug resistanceEconomic DevelopmentEpidemiologyEvolutionFolic Acid AntagonistsGenesGenetic MarkersGenetic PolymorphismGenetic Population StudyGenetic VariationGenotypeGeographic DistributionGoalsHaplotypesHealth BenefitHumanIn VitroIndividualInfectionInterventionIslandLeadLifeLongevityMalariaMeasuresMethodsMicrosatellite RepeatsMolecularMolecular EpidemiologyMonitorMorbidity - disease rateMorphologyMutationParasitesPatientsPatternPharmaceutical PreparationsPhenotypePlasmodium falciparumPoint MutationPoliciesPopulationPrevalenceProvincePublic HealthPyrimethaminePyrimethamine-SulfadoxineRelapseReportingResearchResistanceRiskSingle Nucleotide PolymorphismSoutheastern AsiaStructureSulfadoxineSulfadoxine-pyrimethamine resistanceSuspension substanceSuspensionsVariantVivax Malariaabstractingbasecombatdisorder controlgeographic populationin vivopopulation genetic structureprogramspublic health prioritiesresistance mutationresistant straintransmission process
项目摘要
Project Summary/Abstract
Malaria remains a serious public health problem in China. In the subtropical
Yunnan Province and the tropical Hainan Island of China, malaria has been the most
endemic with high transmission of both Plasmodium falciparum and P. vivax. However,
most of the attention in terms of research and interventions have been focused in
Africa and Southeast Asia, very few studies of malaria in China have been conducted.
Because of extensive use, chloroquine (CQ) has now lost its efficacy due to the
emergence of resistant strains in most parts of the world. Meanwhile, suspension of the
use of CQ has resulted in reappearance of CQ sensitivity. However, there were
differences in the evolution of CQ resistance between parasites from Yunnan and
Hainan, the exact mechanism needs to be investigated. Sulfadoxine-pyrimethamine
(SP) targets the dhfr and dhps genes of P. falciparum, and point mutations that confer
resistance have been widely reported worldwide. Documenting the identity and extent
of SP resistance is also critical for policy decisions regarding antimalarial drugs. In
addition, P. vivax causes a large burden of morbidity in the world including China but
traditionally has been understudied. Based on these, our long-term goal of this
proposal is 1) to identify single-nucleotide polymorphism (SNP) and characterize the
geographic distribution of genetic diversity, population structure, and haplotype
variability at drug resistant loci of P. falciparum from Yunnan and Hainan, China, 2) to
examine the geographic population structure, levels of genetic diversity of P. vivax
using microsatellite and SNP, and 3) to yield valuable information for making more
effective malaria control policies in China. In the past several years we have developed
the molecular methods to study the genetics, population diversity, and evolution of
malaria parasites, and have done some preliminary studies on malaria field isolates
from Yunnan and Hainan using genetic markers, thus enabling us to study the
molecular epidemiology of these important malaria parasites in this proposal. The
specific aims are to:
1. Determine genetic polymorphisms associated with CQ resistance (CQR) in P.
falciparum field isolates from Yunnan and Hainan provinces, China.
2. Determine the point mutation prevalence in the dhfr (pyrimethamine drug
resistance) and dhps (sulfadoxine drug resistance) genes associated with SP
resistance in P. falciparum field isolates from Yunnan and Hainan provinces, China.
3. Assess the changes of P. vivax genotypes using pvcsp, pvmsp1, pvmsp3-¿
genes, and microsatellite markers and determine the geographic structure and
specific epidemiological characteristics of P. vivax transmission in Yunnan and Hainan,
China.
1
项目总结/摘要
疟疾在中国仍然是一个严重的公共卫生问题。亚热带
云南省和热带的中国海南岛,疟疾一直是最多的
恶性疟原虫和间日疟原虫的高度传播。然而,在这方面,
在研究和干预方面,大部分注意力都集中在
非洲和东南亚,中国对疟疾的研究很少。
由于广泛使用,氯喹(CQ)现已因其毒性而失去功效
在世界大部分地区出现耐药菌株。与此同时,
CQ的使用导致CQ敏感性的再现。但有
云南省寄生虫对氯喹抗性的进化差异
海南,确切的机制需要调查。效磺胺
(SP)靶向恶性疟原虫的dhfr和dhps基因,
耐药性已在世界范围内广泛报道。记录身份和范围
SP耐药性的评估对于有关抗疟药物的决策也至关重要。在
此外,间日疟原虫在包括中国在内的世界范围内造成了巨大的发病负担,
传统上被低估了。基于这些,我们的长期目标,
建议是1)鉴定单核苷酸多态性(SNP)并表征
遗传多样性、群体结构和单倍型的地理分布
中国云南和海南省恶性疟原虫耐药基因座的变异,2)
研究间日疟原虫的地理种群结构、遗传多样性水平
利用微卫星和SNP,3)产生有价值的信息,
中国有效的疟疾控制政策。在过去的几年里,我们开发了
研究遗传学、种群多样性和进化的分子方法
疟原虫,并对疟疾现场分离株进行了初步研究
从云南和海南使用遗传标记,从而使我们能够研究
这些重要的疟疾寄生虫的分子流行病学。的
具体目标是:
1.确定与CQ抗性(CQR)相关的遗传多态性。
云南和海南省的恶性疟原虫田间分离株。
2.确定DHFR(乙胺嘧啶药物)中的点突变率
与SP相关的dhps(磺胺类药物抗性)基因
中国云南省和海南省恶性疟原虫田间分离株的耐药性。
3.利用pvcsp、pvmsp 1、pvmsp 3 - 3基因型评估间日疟原虫基因型的变化
基因和微卫星标记,并确定地理结构,
云南和海南间日疟原虫传播的流行病学特征,
中国
1
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fangli Lu其他文献
Fangli Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fangli Lu', 18)}}的其他基金
Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
- 批准号:
8333855 - 财政年份:2009
- 资助金额:
$ 4.77万 - 项目类别:
Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
- 批准号:
8103139 - 财政年份:2009
- 资助金额:
$ 4.77万 - 项目类别:
Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
- 批准号:
7691785 - 财政年份:2009
- 资助金额:
$ 4.77万 - 项目类别:
相似海外基金
Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
- 批准号:
MR/X030202/1 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
- 批准号:
10742205 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
- 批准号:
10635649 - 财政年份:2023
- 资助金额:
$ 4.77万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10534667 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
- 批准号:
2749037 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
- 批准号:
468862 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10368441 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10663334 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别: